Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583557 · ClinicalTrials.gov registry record · Phase 2
A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
A Phase 2 study, sponsored by Human Genome Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00583557 is a Phase 2 study that was terminated before completion, run by Human Genome Sciences. The registered enrollment target is 155 participants.
The verdict
NCT00583557, a Phase 2 study, was terminated before completion, sponsored by Human Genome Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.
Interventions
- DRUG belimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583557
The ClinicalTrials.gov registry entry for NCT00583557 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which belimumab is the first listed.
NCT00583557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583557 about?
NCT00583557 is a clinical study titled "A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01". This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.
What is the current status of trial NCT00583557?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2005-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00583557?
The interventions under investigation include: belimumab (DRUG).
Who is sponsoring clinical trial NCT00583557?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.